Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beltavac is a glutaraldehyde-polymerized allergenic extract (allergoid) derived from the house dust mite species *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. Developed by Probelte Pharma, it is designed for subcutaneous allergen immunotherapy (SCIT) to treat allergic rhinitis and rhinoconjunctivitis, including cases associated with asthma. The polymerization process with glutaraldehyde modifies the allergens to reduce their IgE-binding capacity (allergenicity) while preserving their ability to stimulate T cells (immunogenicity). This modification enhances the safety profile, allowing for the administration of higher allergen doses to induce immune tolerance and desensitization more effectively than native extracts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on house dust mites allergoid.